Stock Research: AstraZeneca

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

AstraZeneca

LSE:AZN GB0009895292
38
  • Value
    12
  • Growth
    59
  • Safety
    Safety
    56
  • Combined
    23
  • Sentiment
    65
  • 360° View
    360° View
    38
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

AstraZeneca PLC is a biopharmaceutical company that discovers, develops, and commercializes prescription medicines. It operates in oncology, rare diseases, and biopharmaceuticals. In the last fiscal year, the company had a market cap of $216,842 million, profits of $44,415 million, revenue of $54,073 million, and 94,300 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 38 (better than 38% compared with alternatives), overall professional sentiment and financial characteristics for the stock AstraZeneca are below the industry average. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for AstraZeneca. The consolidated Value Rank has an attractive rank of 56, which means that the share price of AstraZeneca is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 56% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 59, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 65. But the company’s financing is risky with a Safety rank of 12. This means 88% of comparable companies have a safer financing structure than AstraZeneca. ...read more

more
Index
FTSE All Shares
FTSE 100
FTSE 350
Employee Focus EU
Diversity Europe
Human Rights
Renewables Users
NASDAQ
OMX 30
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
56 46 43 60
Growth
59 48 73 81
Safety
Safety
12 7 10 47
Sentiment
65 45 88 90
360° View
360° View
38 23 53 90
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
78 69 78 67
Opinions Change
40 19 52 52
Pro Holdings
n/a 87 92 80
Market Pulse
43 35 35 59
Sentiment
65 45 88 90
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
56 46 43 60
Growth
59 48 73 81
Safety Safety
12 7 10 47
Combined
23 15 28 70
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
65 51 51 58
Price vs. Earnings (P/E)
26 26 28 44
Price vs. Book (P/B)
15 18 15 34
Dividend Yield
73 71 74 70
Value
56 46 43 60
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
39 55 67 76
Profit Growth
62 42 60 74
Capital Growth
82 37 64 53
Stock Returns
39 67 42 68
Growth
59 48 73 81
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
18 20 20 9
Refinancing
7 6 7 96
Liquidity
41 54 44 32
Safety Safety
12 7 10 47

Similar Stocks

Discover high‑ranked alternatives to AstraZeneca and broaden your portfolio horizons.

Perrigo

NYSE:PRGO
Country: Ireland
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.

BUSE:RICHTER
Country: Hungary
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Ipsen

ENXTPA:IPN
Country: France
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Smith & Nephew

LSE:SN.
Country: United Kingdom
Industry: Health Care Equipment
Size: Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.